Margaret A. Horn, Chief Operating Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), sold 4,583 shares of the company's common stock on March 17, 2026, according to a Form 4 filed with the U.S. Securities and Exchange Commission. The shares transacted at $99.48 each, producing total proceeds of $455,918.
The disposition took place while RVMD shares were trading near a 52-week high of $124.49, following a 156% increase in the stock price over the prior 12 months. After the March 17 sale, Horn's direct ownership in Revolution Medicines stands at 157,570 shares, a figure that includes 73,050 restricted stock units.
The insider sale was carried out pursuant to a Rule 10b5-1 trading plan that Horn adopted on May 31, 2023. The plan was implemented to address tax liabilities arising from the vesting of restricted stock units that vested after July 15, 2023.
Company financials and recent operational updates
Revolution Medicines reported fourth-quarter 2025 results showing an 87% year-over-year increase in its net loss. The company posted earnings per share of negative $1.86, missing the consensus estimate of negative $1.58. The shortfall was attributed to higher-than-expected research and development expenses.
At the end of the quarter, Revolution Medicines held $2.03 billion in cash and investments. The company’s cash position was supported in part by a strategic arrangement with Royalty Pharma, referenced in the quarterly disclosures.
Analyst commentary and market positioning
Several brokerages updated their views on Revolution Medicines following the earnings release. UBS initiated coverage with a Buy rating and highlighted the potential of the company’s RAS inhibitors in treating a range of solid tumors. Piper Sandler raised its price target to $120 while keeping an Overweight rating. Needham lowered its price target to $145 citing higher costs but maintained a Buy rating. Wells Fargo increased its price target to $144 and signaled confidence in the company’s clinical progress, specifically noting developments in second-line pancreatic ductal adenocarcinoma trials.
Separately, InvestingPro analysis cited in filings and commentary indicates that, based on Fair Value metrics, the stock appears overvalued at current levels. The InvestingPro platform is noted as offering 12 additional ProTips for investors seeking further perspective on RVMD.
Context and balance
The insider sale, executed under an established Rule 10b5-1 plan, occurred within a broader company context that includes expanding R&D spending, a sizable cash balance bolstered by a strategic financing arrangement, and a range of analyst opinions that reflect confidence in the clinical pipeline alongside concern about increased costs and valuation. These simultaneous signals underscore the combination of clinical-stage risk and market valuation dynamics affecting the biotech and healthcare sectors.